Discussion panel: Strategies for the successful commercialisation of CART and gene therapies
- Strategies for dealing with the regulators and regulatory submissions
- What does commercialisation mean from a facility point of view?
- Process validation strategies
- How do you plan and strategize to get a commercial process up and running?
- Re-imbursement strategies (working with payers etc.)
Peter Olagunju -
Senior Director, Technical Operations,
bluebird bio, USA
Prentice Curry -
Vice President, Quality and Compliance,
Kite Pharma, USA
Rohit Batta -
Head of Global Medical Affairs Gene Therapy,
Rodney Rietze -
Lead, cGMP and Automation, Cell and Gene Therapies,